Proquility Private Wealth Partners LLC cut its stake in HCA Healthcare, Inc. (NYSE:HCA – Free Report) by 55.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,202 shares of the company’s stock after selling 1,497 shares during the quarter. Proquility Private Wealth Partners LLC’s holdings in HCA Healthcare were worth $361,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in HCA. FMR LLC boosted its stake in shares of HCA Healthcare by 322.3% during the 3rd quarter. FMR LLC now owns 3,141,769 shares of the company’s stock worth $1,276,909,000 after acquiring an additional 2,397,883 shares in the last quarter. Franklin Resources Inc. grew its position in shares of HCA Healthcare by 11.7% in the third quarter. Franklin Resources Inc. now owns 1,669,721 shares of the company’s stock valued at $660,842,000 after purchasing an additional 174,946 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in HCA Healthcare by 2.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,487,367 shares of the company’s stock valued at $604,511,000 after purchasing an additional 41,190 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of HCA Healthcare by 12.0% in the third quarter. Janus Henderson Group PLC now owns 1,339,638 shares of the company’s stock valued at $544,467,000 after buying an additional 143,995 shares during the last quarter. Finally, Darsana Capital Partners LP grew its stake in HCA Healthcare by 53.3% during the 2nd quarter. Darsana Capital Partners LP now owns 1,150,000 shares of the company’s stock valued at $369,472,000 after acquiring an additional 400,000 shares in the last quarter. 62.73% of the stock is owned by hedge funds and other institutional investors.
HCA Healthcare Stock Up 2.6 %
HCA opened at $318.47 on Wednesday. The company has a market cap of $80.67 billion, a PE ratio of 14.30, a P/E/G ratio of 1.06 and a beta of 1.64. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71. The business has a 50 day moving average price of $315.74 and a two-hundred day moving average price of $353.08. HCA Healthcare, Inc. has a 52 week low of $278.68 and a 52 week high of $417.14.
HCA Healthcare Announces Dividend
Insider Transactions at HCA Healthcare
In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the sale, the insider now directly owns 6,843 shares in the company, valued at approximately $2,415,579. The trade was a 29.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Phillip G. Billington sold 3,897 shares of the firm’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the completion of the sale, the senior vice president now owns 52,702 shares of the company’s stock, valued at $18,445,700. This trade represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on HCA. Cantor Fitzgerald reiterated an “overweight” rating and set a $392.00 price objective on shares of HCA Healthcare in a research report on Tuesday, October 1st. StockNews.com downgraded HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. KeyCorp reduced their price target on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Raymond James downgraded shares of HCA Healthcare from an “outperform” rating to a “market perform” rating in a research report on Friday, November 22nd. Finally, Oppenheimer raised their price target on HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a research note on Monday, October 28th. One analyst has rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $385.27.
Read Our Latest Report on HCA Healthcare
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Further Reading
- Five stocks we like better than HCA Healthcare
- Do ETFs Pay Dividends? What You Need to Know
- SAP’s Strong Momentum: A Bullish Setup for Investors
- How to Use the MarketBeat Excel Dividend Calculator
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.